Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 3 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
5 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.

Short-course TB treatment improves completion rates in paediatric patients

10 Feb 2018

The use of shorter treatment regimens in children with tuberculosis (TB) infection leads to increased rates of completion and fewer adverse events (AEs) when compared with 9 months of daily isoniazid (9H) treatment, a study has shown.

Researchers reviewed the medical records of 667 children with TB infection (median age 8 years; 50.8 percent female) who received 9H (n=252), 4 months of daily rifampin (4R; n=132) or 3 months of once-weekly isoniazid and rifapentine (3HP; n=283).

The 4R and 9H regimens could be administered by families (self-administered therapy [SAT]) or as directly observed preventive therapy (DOPT). On the other hand, 3HP was always administered under DOPT.

Completion rates were highest with 3HP (96.8 percent) and lowest with 9H under SAT (52.6 percent; odds ratio [OR], 27.4; 95 percent CI, 11.8–63.7). When administered under DOPT, 9H had a completion rate of 89 percent (vs 9H under SAT: OR, 7.11; 3.54–14.28). The rates did not significantly differ between 3HP and 4R under DOPT (OR, 1.12; 0.14–9.09).

On multivariable regression analysis, completion of therapy was associated with the following factors: receipt of medication under DOPT (OR, 5.72; 3.47–9.43), increasing age (OR, 1.09; 1.02–1.17) and the absence of any AE (OR, 1.70; 0.26–0.60).

There were 62 children (9.3 percent) overall with complaints of any AE, which occurred frequently in the 9H group (OR, 2.51; 1.48–4.32). Hepatotoxicity was reported in two (0.9 percent) children in the 9H group in none in the 3HP and 4R groups.

The present data indicate that the 3HP and 4R regimens are well tolerated and associated with significantly higher completion rates compared with 9H, with the effectiveness of these short-course regimens being high in the short-term, researchers said.

“We hope that the coming years will see a shift in TB infection diagnosis to IGRAs to enable treatment to target the children who would receive the most benefit from therapy, and that increased data on 3HP pharmacokinetics and more child-friendly formulations of 3HP will enable this shorter regimen to be used in the most vulnerable paediatric population: infants and young children,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 3 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
5 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.